Miromatrix Medical announced that it was informed via e-mail from the FDA that the miroliverELAP Investigational New Drug, or IND, application for the treatment of acute liver failure has been placed on clinical hold. The miroliverELAP IND application was submitted in mid-November. The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days. Miromatrix plans to provide additional updates pending communication with the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MIRO:
- Miromatrix Plunges After Clinical Hold
- Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP
- Miromatrix Announces Participation in the Piper Sandler 34th Annual Healthcare Conference
- Miromatrix Medical price target raised to $9 from $8 at Piper Sandler
- Miromatrix Medical reports Q3 EPS (37c), two estimates (40c)